Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Haematology & Bone Marrow Transplant
Car-t for multiple myeloma
What CAR-T cell therapy for multiple myeloma is, how chimeric antigen receptor T-cells target BCMA on plasma cells, what clinical trials and haematologists report about remission rates, approximate costs in Turkey compared with the UK, US and Germany, the step-by-step hospital timeline from apheresis to infusion, serious immune risks, recovery milestones and how to choose an accredited cancer centre.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Haematology & Bone Marrow Transplant
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for CAR-T for Multiple Myeloma
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
CAR-T for multiple myeloma in Turkey: what it is and how it works
CAR-T for multiple myeloma is an advanced cellular immunotherapy engineered to target and eliminate malignant plasma cells in relapsed or refractory disease. Rather than using conventional chemotherapy to attack cancer cells directly, chimeric antigen receptor (CAR) T-cell therapy reprogrammes a patient’s own immune system. Specialised T-lymphocytes are collected from blood, genetically altered in a cell laboratory to produce synthetic receptors targeting B-cell maturation antigen (BCMA) on myeloma cells, expanded into millions of cells, and reinfused into the bloodstream. International patients exploring car-t for multiple myeloma in Turkey are treated in specialised haematology centres equipped with dedicated cell-therapy units.
Multiple myeloma is a haematological cancer of bone marrow plasma cells causing bone lesions, anaemia, kidney complications, and infections. While initial therapies often achieve remission, the disease frequently returns. CAR-T therapy provides a targeted option for patients whose cancer has progressed through standard drug classes. For wider cancer care options, see our guide to oncology treatments in Turkey.
How does CAR-T cell therapy target multiple myeloma cells?
The therapy relies on precision antigen recognition. Multiple myeloma cells display B-cell maturation antigen (BCMA) across their surface, a protein vital for plasma cell survival but absent from most healthy tissues. In the laboratory, a disarmed viral vector introduces a synthetic gene into the harvested T-cells, enabling them to express chimeric antigen receptors that bind specifically to BCMA.
After short conditioning chemotherapy, the engineered cells are infused into the bloodstream. When they encounter BCMA-bearing myeloma cells, they attach, release cytotoxic granules to dissolve the cancer cells, and stimulate further immune activity. These living cells can persist in bone marrow for months, providing sustained surveillance against residual disease.
Does CAR-T work for multiple myeloma? What clinical evidence shows
Published clinical trials and international haematology registries show that BCMA-directed CAR-T therapy produces high response rates in advanced disease. Studies evaluate overall response rates between 70% and 85% in patients with relapsed or refractory multiple myeloma, with many achieving complete remission and minimal residual disease (MRD) negativity. For individuals who have exhausted standard chemotherapy regimens, this offers substantial therapeutic progress.
However, CAR-T is not an established permanent cure. Disease recurrence can still occur over time if malignant cells shed BCMA or infused T-cells become exhausted. Remission duration depends on disease biology, prior treatments, and overall physical health. Realistic clinical consultations focus on prolonging progression-free survival and symptom relief rather than promising total eradication.
CAR-T for multiple myeloma cost in Turkey compared with the UK, US and Germany
Cellular immunotherapy costs reflect complex laboratory engineering, cleanroom manufacturing, inpatient hospitalisation, and intensive care readiness. The table below outlines approximate cost ranges per complete treatment cycle across countries, including cell collection, manufacturing, conditioning, infusion, and acute post-infusion monitoring.
| Country | Approximate cost range |
|---|---|
| Turkey | €70,000 – €150,000 |
| United Kingdom | €300,000 – €550,000 |
| United States | €400,000 – €750,000 |
| Germany | €280,000 – €480,000 |
Several elements influence the overall car-t for multiple myeloma price. Academic and hospital manufacturing protocols generally cost less than commercial pharmaceutical products. Additional variables include bridging chemotherapy while cells are produced, intensive care days for immune side effects, and supportive medicines like tocilizumab. Packages typically cover pre-infusion staging, leukapheresis, conditioning, two to three weeks of inpatient accommodation, and initial laboratory panels. Request a breakdown with a free quote based on your haematology files.
CAR-T cell therapy, bispecific antibodies or stem cell transplant?
Managing advanced multiple myeloma requires matching the treatment modality to disease stage, prior therapies, and patient fitness.
| Treatment modality | Best suited to | Typical limits |
|---|---|---|
| BCMA CAR-T cell therapy | Relapsed or refractory myeloma after triple-class exposure (IMiD, PI, anti-CD38) | Requires manufacturing lead time, specialised inpatient cell monitoring, risk of CRS and ICANS |
| Bispecific T-cell engagers (TCEs) | Patients requiring immediate off-the-shelf treatment without waiting for cell culture | Requires continuous or indefinite repeated cycles, ongoing infection risk, cumulative fatigue |
| Autologous stem cell transplant (ASCT) | Newly diagnosed, transplant-eligible patients responding to initial induction therapy | Uses non-targeted high-dose chemotherapy; limited durability in heavily pre-treated relapse |
Bispecific antibodies provide an immediate option without manufacturing delays, though they require ongoing administration. CAR-T offers a single infusion that can yield extended treatment-free remissions. For broader treatment perspectives, see our guide to oncology treatments in Turkey.
Who is an eligible candidate for myeloma CAR-T therapy?
Candidate selection is strict due to the physical demands of cellular therapy. Eligible candidates are generally adults with multiple myeloma that has relapsed after at least three prior treatment classes, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients need adequate bone marrow reserve, satisfactory cardiac, pulmonary, hepatic, and renal function, and an ECOG performance status of 0 to 2.
Individuals with active uncontrolled systemic infections, severe organ failure, or uncontrolled secondary cancers are not suitable candidates. Pre-treatment evaluation includes bone marrow biopsies, PET-CT scans, echocardiograms, and pulmonary testing to verify treatment safety.
The treatment process: from T-cell collection to infusion
The CAR-T treatment pathway involves five clinical stages. First is evaluation and leukapheresis, an outpatient procedure where white blood cells are separated and harvested from the blood over three to five hours. The collected cells are cryopreserved and sent for laboratory engineering.
Second is manufacturing and bridging therapy. Modifying and culturing T-cells takes two to four weeks; during this period, bridging chemotherapy or radiation may be given to control myeloma growth. Third is conditioning chemotherapy: two to three days of fludarabine and cyclophosphamide to clear space for the new cells. Fourth is the intravenous infusion of engineered T-cells, lasting 15 to 30 minutes. Fifth is inpatient monitoring for 10 to 14 days to observe and manage acute immune reactions.
Treatment timeline and CAR-T for multiple myeloma recovery
International medical travel for CAR-T therapy requires five to eight weeks abroad. This encompasses pre-treatment checks, cell harvesting, conditioning, inpatient hospitalisation, and local outpatient convalescence within reach of the hospital.
Recovery follows distinct milestones:
- Days 1 to 14: Inpatient stay with continuous monitoring for fevers, blood pressure changes, and neurological symptoms.
- Days 15 to 30: Local outpatient recovery with frequent blood tests, electrolyte management, and infection screening.
- Months 1 to 3: Gradual stamina improvement as neutrophil and platelet counts recover under antimicrobial precautions.
- Months 3 to 6: Comprehensive restaging via marrow biopsy, PET-CT, and protein panels, followed by planned revaccinations.
Low blood counts and fatigue are common during car-t for multiple myeloma recovery. Patients are usually cleared to fly home around day 28 to 35 post-infusion if clinical markers remain stable.
Remission expectations and before-and-after monitoring
Because multiple myeloma is a blood cancer, outcomes are tracked through laboratory analyses and imaging rather than visual photographs. Prior to therapy, evaluations typically show elevated serum paraprotein (M-spike), abnormal free light chain ratios, osteolytic bone lesions, and high plasma cell counts in marrow biopsies.
After treatment, success is measured by response depth. Complete response involves the disappearance of measurable paraprotein, while minimal residual disease (MRD) testing checks for fewer than one cancer cell in a million marrow cells. Sustained remission brings symptom relief and reduced bone pain. Routine blood panels and imaging continue every three months to monitor disease status.
Risks, side effects and safety considerations
CAR-T therapy carries significant risks outlined by organisations such as the US FDA, EMA, and the European Society for Blood and Marrow Transplantation (EBMT). The two primary acute toxicities are Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).
CRS occurs as multiplying T-cells release inflammatory cytokines, causing fevers, blood pressure drops, and low oxygen. Mild cases are managed with fluids, while severe cases require tocilizumab and corticosteroids. ICANS affects the nervous system, producing confusion, speech difficulty, or tremors. Patients also face prolonged low blood counts and temporary immune suppression, requiring antibiotic prophylaxis against infections.
Choosing a specialised treatment centre and questions to ask
Due to the complexity of cellular therapy, patients should select accredited institutions with JACIE or JCI certification. The hospital must feature dedicated haematology wards, an on-site intensive care unit with 24-hour coverage, and immediate access to rescue drugs like tocilizumab. To understand how international patient logistics are managed, explore how it works before travelling.
Avoid clinics that offer cell therapies in outpatient settings without emergency facilities, fail to itemise cell manufacturing costs, or claim certain cures. Submit your medical records for a confidential free quote to evaluate your options. Review our guide on how it works to prepare your journey. Consider asking your clinical team:
- How many cellular therapy procedures and transplants does your haematology unit handle each year?
- What laboratory manufactures the CAR-T cells, and what is the expected turnaround time?
- What bridging therapy options are planned if my disease accelerates during manufacturing?
- Is an intensive care bed immediately accessible on-site if complications arise?
- Which medications, such as tocilizumab and immunoglobulins, are covered in the package quote?
- What follow-up plan and infection guidance will be provided for my local haematologist?
Conditions treated with CAR-T for Multiple Myeloma
Hospitals with Oncology in Turkey
Frequently asked questions
CAR-T cell therapy for multiple myeloma is an advanced cellular immunotherapy that uses genetically re-engineered versions of a patient’s own T-lymphocytes. The modified T-cells express synthetic chimeric antigen receptors targeting B-cell maturation antigen (BCMA) on malignant plasma cells. Once reinfused, they multiply and destroy myeloma cells throughout the bone marrow.
Clinical trials and real-world haematology registries indicate that BCMA-directed CAR-T therapy achieves overall response rates between 70% and 85% in patients with relapsed or refractory multiple myeloma. Many patients achieve minimal residual disease negativity. While it produces durable remissions for individuals with limited remaining options, it is not currently considered a permanent cure.
In Turkey, CAR-T cell therapy programmes generally range between €70,000 and €150,000, depending on the manufacturing protocol and hospital package. In the UK, US, and Germany, commercial costs often exceed €300,000 to €550,000. Packages typically include cell collection, conditioning chemotherapy, hospitalisation, and monitoring for acute complications.
An autologous stem cell transplant uses high-dose chemotherapy to destroy the bone marrow before rescuing blood production with harvested stem cells. In contrast, CAR-T therapy genetically re-engineers immune T-cells to specifically target and attack myeloma surface markers. CAR-T is typically offered when myeloma relapses after stem cell transplantation.
The most significant acute risks are Cytokine Release Syndrome (CRS) and immune neurotoxicity (ICANS). Symptoms range from fevers, low blood pressure, and racing heartbeat to confusion, speech difficulty, and tremors. Prolonged low blood cell counts and increased susceptibility to viral and bacterial infections are also common and require prolonged prophylaxis.
Eligibility usually requires an adult diagnosis of multiple myeloma that has relapsed or progressed after at least three prior therapy classes, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients must have adequate heart, lung, liver, and kidney function, alongside an acceptable physical performance score.
Acute recovery takes two to four weeks under direct hospital surveillance to manage fevers and immune reactions. Outpatient recovery continues for another two to four weeks near the hospital. Full blood count normalisation and immune reconstitution usually require three to six months of regular haematology reviews and antimicrobial precautions.
The leukapheresis and cell infusion stages do not cause sharp pain, resembling routine intravenous procedures and transfusions. However, conditioning chemotherapy can cause nausea and fatigue. If cytokine release syndrome occurs, patients experience high fevers, body aches, chills, and weakness, which are managed promptly with intravenous supportive medications in the hospital.
Remission duration varies based on disease biology, prior treatments, and genetic risk factors. Clinical trials report median progression-free survival ranging from one to over two years, with some patients enjoying several years of treatment-free remission. However, multiple myeloma can eventually recur if malignant cells stop expressing BCMA or T-cells exhaust.
International patients typically stay in Turkey for five to eight weeks. This duration covers pre-treatment staging, leukapheresis, bridging therapy, conditioning chemotherapy, cell infusion, two weeks of inpatient observation, and an additional two to three weeks of outpatient monitoring near the hospital before safe clearance to fly.
Patient stories